Lung cancer
Conditions
Interventions
Leisure-Time Physical Activity (LTPA) Group:Leisure-Time Physical Activity (LTPA) Group:
Patients were classified based on questionnaire responses regarding their prior exercise habits. Individuals in
Non-Exercise Group:Non-Exercise Group:
Patients who reported no regular physical activity habits were classified into the non-exercise group.
Sponsors
Mindong Hospital of Ningde City
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Pathologically confirmed diagnosis of advanced non-small cell lung cancer (NSCLC), specifically stage IIIB, IIIC, or IV; (2) Aged between 18 and 80 years; (3) Eastern Cooperative Oncology Group (ECOG) performance status of 0–1: 0: Fully active, with no restrictions on daily activities; 1: Restricted in physically strenuous activity, may experience mild fatigue or discomfort, but capable of performing daily activities; (4) Wild-type for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK); (5) Receiving first-line treatment with PD-1 inhibitors in combination with platinum-based chemotherapy, and an expected survival of at least 6 months; (6) Leisure-time physical activity (LTPA) group: patients voluntarily engage in physical activity (not mandatory or work-related), with a clear habit of LTPA—defined as at least 150 minutes of moderate-intensity activity (=3 metabolic equivalents, METs) per week, or at least 75 minutes of vigorous-intensity activity (=6 METs) per week. Non-exercise group: patients without regular physical activity habits; (7) Availability of complete research data, including clinical, laboratory, and imaging follow-up records.
Exclusion criteria
Exclusion criteria: (1) Patients with major comorbidities (e.g., severe cardiovascular or cerebrovascular diseases); (2) Patients who have previously received other treatments for advanced NSCLC, including local radiotherapy, chemotherapy alone, or targeted therapy; (3) Patients with neurological or psychiatric disorders who are unable to cooperate with the study; (4) Incomplete clinical follow-up data, making it impossible to assess the efficacy of immunotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolites and Peripheral Blood Proteins;Gut Microbiota; | — |
Countries
China
Contacts
Public ContactLiu Qixi/Ye Xinxin
Mindong Hospital of Ningde City
Outcome results
None listed